IP Library Granted Patent US 8,298,568
Granted Patent B2
US 8,298,568 · App. 10/991,346 · Granted Oct 30, 2012

Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential

Assignee: Novagali Pharma SA
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,298,568
App. No.
10/991,346
Granted
Oct 30, 2012
Kind
B2
Abstract

A well tolerated oil-in-water emulsion useful as a delivery vehicle of hydrophobic ingredients such as pharmaceutical drugs, wherein the emulsion particles have a net positive charge and comprises 0.001 to 0.1% of a cationic agent, 0 to 1% of a non ionic surfactant and 0 to 0.5% of an anionic surfactant.

Claims (14)

1. An oil-in-water emulsion, comprising:

colloid particles having an oily core surrounded by an interfacial film;

said interfacial film having an overall positive charge and comprising, based on total emulsion weight:

1) 0.001 to 0.05% by weight of a cationic agent, said cationic agent being cetalkonium chloride,

2) a non ionic surfactant, said nonionic surfactant being present in an amount up to 1% by weight and consisting of tyloxapol and poloxamer, and

3) 0% by weight of phospholipids; and

said oil core being not higher than 5% weight.

2. The oil-in-water emulsion according to claim 1 , wherein the concentration of the oily core is about 0.5 to 3% w/w.

3. The oil-in-water emulsion according to claim 1 , wherein said colloidal particles have an average particle size of about 0.1 to 1 μm.

4. The oil-in-water emulsion according to claim 3 , wherein said colloidal particles have an average particle size of about 300 nm.

5. The oil-in-water emulsion according to claim 3 , wherein said colloidal particles have an average particle size of about 100 to 200 nm.

6. A pharmaceutical composition comprising a pharmaceutically effective amount of a well tolerated carrier with an active ingredient, said carrier being an oil-in-water emulsion according to claim 1 .

7. The pharmaceutical composition according to claim 6 , wherein said composition is an ophthalmic preparation.

8. The pharmaceutical composition according to claim 6 , wherein the active ingredient is sirolimus.

Assignments (3)
CHANGE OF ADDRESS Recorded Feb 20, 2025
From: SANTEN
To: SANTEN
Reel/Frame 070276/0582 →
CHANGE OF NAME Recorded Feb 25, 2014
From: NOVAGALI PHARMA SA
To: SANTEN SAS
Reel/Frame 032332/0471 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2005
From: BAGUE, SEVERINE; PHILIPS, BETTY; GARRIGUE, JEAN-SEBASTIEN; LAMBERT, GREGORY; RABINOVICH-GUILATT, LAURA
To: NOVAGALI PHARMA SA
Reel/Frame 016293/0024 →
Priority Claims (1)
EP 04292645 · Nov 9, 2004 · regional
Continuity (1)
Related Publication 20060100288A1 · May 11, 2006